SHARON, Pa., Aug. 1 /PRNewswire-FirstCall/ -- NanoLogix, Inc. , a nano-biotechnology company engaged in the development and commercialization of technologies for the creation of hydrogen bioreactors, today announced that it was featured in the August edition of The Florida Investor, Florida’s premier business investment publication. The article, “Take Stock In The Future NanoLogix, Inc. -- Creating the Future’s Alternative Fuel Source Today,” can be viewed online at http://www.otcfn.com/nnlx or http://www.floridainvestor.net.
An excerpt from the article stated, “According to the company, NanoLogix is presently in negotiations with multiple large corporations for the joint venture development of hydrogen bioreactors as a viable fuel source. A completion of such a joint venture would dramatically accelerate the time in which the alternative fuel source becomes mainstream and the value of the stock.
“In our opinion, NanoLogix is an attractive investment at this juncture due to the fact that the company is, frankly, an undiscovered company in an area that is about to explode on the upside. Can you imagine, our future fuel resource coming from wastewater, waste organic material (citrus), or your garbage can? Well, that is exactly what NanoLogix is up to and all signs point to success.”
About The Florida Investor
The Florida Investor is Florida’s monthly authority on Industrial, Commercial and Investment Real Estate, Emerging Stocks, Franchises and Businesses for Sale. The Florida Investor is distributed state wide with a focused approach, offering a single, consolidated source for reaching thousands of potential investors and potential business partners throughout the State. For more information, visit http://www.floridainvestor.net/.
About NanoLogix, Inc.
NanoLogix is a nano-biotechnology company whose extensive portfolio of patents have application and marketability in the following areas: nanoscale microfluidics for the rapid identification of disease causing pathogens utilizing BioMEMS; production of high value hydrogen from agricultural feedstock, industrial waste water and municipal waste streams; nontoxic induction of apoptosis (a method for inducing a genetically based induction of “cell suicide”) in cancer cells utilizing hydrophobic hydrocarbons; and the bio-remediation of air, water and soils of harmful contaminants. For more information, visit http://www.nanologix.net.
This press release contains statements, which may constitute “forward- looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact: At OTC Financial Network Geoffrey Eiten Investor Relations 781-444-6100x613 geiten@otcfn.comwww.otcfn.com/nnlx
NanoLogix, Inc.
CONTACT: Investor Relations, Geoffrey Eiten at OTC Financial Network,+1-781-444-6100, ext. 613, or geiten@otcfn.com, for NanoLogix, Inc.
